Erythropoietin and erythropoiesis stimulating agents

Drug Testing and Analysis

Volumn 4, Issue 11, 2012, Pages 805-812

  Debeljak, Nataša ^a   Sytkowski, Arthur J ^b,c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b HARVARD MEDICAL SCHOOL   (United States)

^c IQVIA   (United States)

Author keywords

Continuous erythropoiesis receptor activator (CERA); Darbepoetin alfa; Doping; Epoetin; Erythropoiesis stimulating agent (ESA); Recombinant human erythropoietin

Indexed keywords

ELECTROPHORESIS; GENES; MONOCLONAL ANTIBODIES;

CELLS PRODUCTION; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DARBEPOETIN ALPHA; EPOETIN; ERYTHROPOIESIS STIMULATING AGENT; ERYTHROPOIESIS-STIMULATING AGENTS; HUMAN ERYTHROPOIETIN; RECEPTOR ACTIVATOR; RECOMBINANT HUMAN ERYTHROPOIETIN; RED BLOOD CELL;

SPORTS;

ALBUMIN; ANTIANEMIC AGENT; ANTIBODY; BIOSIMILAR AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; CNTO 528; CNTO 530; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; EPOPEN; ERITROGEN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FG 2216; GENE THERAPY AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 3; K 11706; K 7174; MIMETIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AE7A5; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARVOVIRUS VECTOR; PEGINESATIDE; PEPTIDOMIMETIC AGENT; RATIOEPO; RECOMBINANT ERYTHROPOIETIN; RETRACRIT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANEMIA; BINDING AFFINITY; DOPING; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MISUSE; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; IMMUNOBLOTTING; ISOELECTRIC FOCUSING; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SPORT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84870241468     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1341     Document Type: Review

References (108)

1. A.J. Sytkowski Erythropoietin: Blood, Brain and Beyond, Wiley-VCH, Weinheim, Germany, 2004.
2. J.W. Eschbach, J.C. Egrie, M.R. Downing, J.K. Browne, J.W. Adamson Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. New Engl. J. Med. 1987, 316, 73.
3. H.L. Corwin, A. Gettinger, T.C. Fabian, A. May, R.G. Pearl, S. Heard, et al. Efficacy and safety of epoetin alfa in critically ill patients. New Engl. J. Med. 2007, 357, 965.
4. J.D. Rizzo, M. Brouwers, P. Hurley, J. Seidenfeld, M.O. Arcasoy, J.L. Spivak, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J. Clin. Oncol. 2010, 28, 4996.
5. D. Schrijvers, H. De Samblanx, F. Roila, E.G.W. Group Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010, 21, 244.
6. E.M. Moore, R. Bellomo, A.D. Nichol Erythropoietin as a novel brain and kidney protective agent. Anaesth Intens. Care. 2011, 39, 356.
7. A.J. Sytkowski The neurobiology of erythropoietin. Cell. Mol. Neurobiol. 2011, 31, 931.
8. R. Latini, M Brines, F. Fiordaliso Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail. Rev. 2008, 13, 415.
9. M. Brines, A. Cerami Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J. Intern. Med. 2008, 264, 405.
10. D. Thieme, P. Hemmersbach, C. Reichel, G. Gmeiner, in Doping in Sports: Biochemical Principles, Effects and Analysis. Springer, Berlin, Heidelberg, 2010, pp. 251.
11. F. Lasne, J. de Ceaurriz Recombinant erythropoietin in urine. Nature 2000, 405, 635.
12. A.J. Sytkowski, J.W. Fisher Isolation and characterization of an anti-peptide monoclonal antibody to human erythropoietin. J. Biol. Chem. 1985, 260, 14727.
13. R.L. Wilber Detection of DNA-Recombinant Human Epoetin-Alfa as a Pharmacological Ergogenic Aid. Sports Med. 2002, 32, 125.
14. WADA. 2012 Prohibited List. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2012/WADA_Prohibited_List_2012_EN.pdf [27 March 2012].
15. S. Lamon, S. Giraud, L. Egli, J. Smolander, M. Jarsch, K.G. Stubenrauch, et al. A high-throughput test to detect C.E.R.A. doping in blood. J. Pharm. Biomed. Anal. 2009, 50, 954.
16. C. Reichel, F. Abzieher, T. Geisendorfer SARCOSYL-PAGE: a new method for the detection of MIRCERA- and EPO-doping in blood. Drug Test. Analysis 2009, 1, 494.
17. M. Lonnberg, J. Carlsson Membrane assisted isoform immunoassay. A rapid method for the separation and determination of protein isoforms in an integrated immunoassay. J. Immunol. Methods 2000, 246, 25.
18. K. Jacobs, C. Shoemaker, R. Rudersdorf, S.D. Neill, R.J. Kaufman, A. Mufson, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985, 313, 806.
19. F.K. Lin, S. Suggs, C.H. Lin, J.K. Browne, R Smalling, J.C. Egrie, et al. Cloning and expression of the human erythropoietin gene. Proc. Natl Acad. Sci. USA 1985, 82, 7580.
20. P.C. Watkins, R. Eddy, N. Hoffman, P. Stanislovitis, A.K. Beck, J. Galli, et al. Regional assignment of the erythropoietin gene to human chromosome region 7pter----q22. Cytogenet. Cell Genet. 1986, 42, 214.
21. J.S. Powell, K.L. Berkner, R.V. Lebo, J.W. Adamson Human erythropoietin gene: High level expression in stably transfected mammalian cells and chromosome localization. PNAS. 1986, 83, 6465.
22. W. Jelkmann Erythropoietin: structure, control of production, and function. Physiol. Rev. 1992, 72, 449.
23. C. Stockmann, J Fandrey Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin. Exp. Pharmacol. P. 2006, 33, 968.
24. W. Jelkmann Control of erythropoietin gene expression and its use in medicine. Method Enzymol. 2007, 435, 179.
25. S. Frede, P. Freitag, L. Geuting, R. Konietzny, J. Fandrey Oxygen-regulated expression of the erythropoietin gene in the human renal cell line REPC. Blood 2011, 117, 4905.
26. H. Rahbek-Nielsen, P. Roepstorff, H. Reischl, M. Wozny, H. Koll, A. Haselbeck Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom. 1997, 32, 948.
27. P.H. Lai, R. Everett, F.F. Wang, T. Arakawa, E. Goldwasser Structural characterization of human erythropoietin. J. Biol. Chem. 1986, 261, 3116.
28. M.A. Recny, H.A. Scoble, Y. Kim Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J. Biol. Chem. 1987, 262, 17156.
29. S. Dube, J.W. Fisher, J.S. Powell Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J. Biol. Chem. 1988, 263, 17516.
30. A.J. Sytkowski, L. Feldman, D.J. Zurbuch Biological activity and structural stability of N-deglycosylated recombinant human erythropoietin. Biochem. Biophys. Res. Commun. 1991, 176, 698.
31. E. Delorme, T. Lorenzini, J. Giffin, F. Martin, F. Jacobsen, T. Boone, et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 1992, 31, 9871.
32. S. Bachmann, M. Le Hir, K.U. Eckardt Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J. Histochem. Cytochem. 1993, 41, 335.
33. P.H. Maxwell, D.J. Ferguson, L.G. Nicholls, J.P. Iredale, C.W. Pugh, M.H. Johnson, et al. Sites of erythropoietin production. Kidney Int. 1997, 51, 393.
34. S.E. Juul, A.T. Yachnis, R.D. Christensen Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev. 1998, 52, 235.
35. J. Grodberg, K.L. Davis, A.J. Sykowski Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Eur. J. Biochem. 1993, 218, 597.
36. D. Wen, J. Boissel, M. Showers, B. Ruch, H. Bunn Erythropoietin structure-function relationships. Identification of functionally important domains. J. Biol. Chem. 1994, 269, 22839.
37. J.S. Philo, K.H. Aoki, T. Arakawa, L.O. Narhi, J. Wen Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction. Biochemistry 1996, 35, 1681.
38. M.O. Arcasoy The non-haematopoietic biological effects of erythropoietin. Brit. J. Haematol. 2008, 141, 14.
39. W. Jelkmann, K. Wagner Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann. Hematol. 2004, 83, 673.
40. K. Maiese, F. Li, Z.Z. Chong New avenues of exploration for erythropoietin. JAMA 2005, 293, 90.
41. J. Szenajch, G. Wcislo, J.Y. Jeong, C. Szczylik, L. Feldman The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells From clinic to bench - a critical review. Biochim. Biophys. Acta 2010, 1806, 82.
42. A.J. Sytkowski Does erythropoietin have a dark side? EPO signaling and cancer cells. Sci. STKE. 2007, 2007, pe38.
43. A.D. D'Andrea, H.F. Lodish, G.G. Wong Expression cloning of the murine erythropoietin receptor. Cell 1989, 57, 277.
44. S.S. Jones, A.D. D'Andrea, L.L. Haines, G.G. Wong Human erythropoietin receptor: Cloning, expression, and biologic characterization. Blood 1990, 76, 31.
45. J. Winkelmann, L. Penny, L. Deaven, B. Forget, R. Jenkins The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood 1990, 76, 24.
46. L.A. Penny, B.G. Forget Genomic organization of the human erythropoietin receptor gene. Genomics 1991, 11, 974.
47. J.V. Brugniaux, V. Pialoux, G.E. Foster, C.T.C Duggan, M. Eliasziw, P.J. Hanly, et al. Effects of intermittent hypoxia on erythropoietin, soluble erythropoietin receptor and ventilation in humans. Eur. Respir. J. 2011, 37, 880.
48. K.W. Harris, J.C. Winkelmann Enzyme-linked immunosorbent assay detects a potential soluble form of the erythropoietin receptor in human plasma. Am. J. Hematol. 1996, 52, 8.
49. M.F. McMullin, M.J. Percy Erythropoietin receptor and hematological disease. Am. J. Hematol. 1999, 60, 55.
50. E. Juvonen, E. Ikkala, F. Fyhrquist, T Ruutu Autosomal dominant erythrocytosis caused by increased sensitivity to erythropoietin. Blood 1991, 78, 3066.
51. J.T. Prchal, L. Sokol "Benign erythrocytosis" and other familial and congenital polycythemias. Eur. J. Haematol. 1996, 57, 263.
52. R. Kralovics, K. Indrak, T. Stopka, B.W. Berman, J.F. Prchal, J.T. Prchal. Two new EPO receptor mutations: Truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997, 90, 2057.
53. J.F. Bazan Structural design and molecular evolution of a cytokine receptor superfamily. PNAS. 1990, 87, 6934.
54. T. Hosoi, S.T. Sawyer, S.B. Krantz Photoaffinity labeling of the erythropoietin receptor and its identification in a ligand-free form. Biochemistry 1991, 30, 329.
55. S.C. Bailey, R. Spangler, A.J. Sytkowski Erythropoietin induces cytosolic protein phosphorylation and dephosphorylation in erythroid cells. J. Biol. Chem. 1991, 266, 24121.
56. P.J. McCaffery, J.K. Fraser, F.K. Lin, M.V. Berridge Subunit structure of the erythropoietin receptor. J. Biol. Chem. 1989, 264, 10507.
57. J.N. Ihle, B.A. Witthuhn, F.W. Quelle, K. Yamamoto, O. Silvennoinen Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 1995, 13, 369.
58. K.D. O'Neal, L.Y. Yu-Lee The proline-rich motif (PRM): A novel feature of the cytokine/hematopoietin receptor superfamily. Lymphokine. Cytok. Res. 1993, 12, 309.
59. J.W. Tanner, W. Chen, R.L. Young, G.D. Longmore, A.S. Shaw The conserved box1 motif of cytokine receptors is required for association with JAK Kinases. J. Biol. Chem. 1995, 270, 6523.
60. N. Debeljak, A.J. Sytkowski EPOR. UCSD-Nature Molecule pages. 2007. DOI: 10.1038/mp.a000863.01
61. S.S Watowich Activation of erythropoietin signaling by receptor dimerization. Int. J. Biochem. Cell Biol. 1999, 31, 1075.
62. S.J. Frank Minireview: Receptor dimerization in GH and erythropoietin action--It takes two to tango, but how? Endocrinology 2002, 143, 2.
63. I.A. Wilson, L.K. Jolliffe The structure, organization, activation and plasticity of the erythropoietin receptor. Curr. Opin. Struct. Biol. 1999, 9, 696.
64. D.M. Wojchowski, S.H. Orkin, A.J. Sytkowski Active human erythropoietin expressed in insect cells using a baculovirus vector: A role for N-linked oligosaccharide. Biochim. Biophys. Acta 1987, 910, 224.
65. A. Sikole, G. Spasovski, D. Zafirov, M. Polenakovic Epoetin omega for treatment of anemia in maintenance hemodialysis patients. Clin. Nephrol. 2002, 57, 237.
66. B.S. Spinowitz, R.D. Pratt Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr. Med. Res. Opin. 2006, 22, 2507.
67. J.C. Egrie, J.K. Browne Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transpl. 2001, 16, 3.
68. J.C. Egrie, E. Dwyer, J.K. Browne, A. Hitz, M.A. Lykos Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 2003, 31, 290.
69. I.C. Macdougall CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep. 2005, 4, 436.
70. F. Locatelli, G. Villa, A.L. de Francisco, A. Albertazzi, H.J. Adrogue, F.C. Dougherty, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr. Med. Res. Opin. 2007, 23, 969.
71. J.M. Davis, T. Arakawa, T.W. Strickland, D.A. Yphantis Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 1987, 26, 2633.
72. H. Sasaki, B. Bothner, A. Dell, M. Fukuda Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. 1987, 262, 12059.
73. V. Skibeli, G. Nissen-Lie, P. Torjesen Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001, 98, 3626.
74. K. Španinger, N. Debeljak Erythropoietin, epoetins and detection. Pharmaceut. J. Slov. (Farmacevtski vestnik). 2009, 60, 279.
75. F. Lasne, L. Martin, N. Crepin, J. de Ceaurriz Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal. Biochem. 2002, 311, 119.
76. K. Španinger, S. Borštnar, E. Matos, B. Možina, A.J. Sytkowski, R. Komel, et al. Report on isoelectric focusing trial of erythropoietin profiling in two cancer patients during chemotherapy and darbepoetin treatment. Acta Chim. Slov. 2011, 58, 139.
77. F. Lasne, L. Martin, J.A. Martin, J. de Ceaurriz Isoelectric profiles of human erythropoietin are different in serum and urine. Int. J. Biol. Macromol. 2007, 41, 354.
78. F. Lasne, J. Thioulouse, L. Martin, J. de Ceaurriz Detection of recombinant human erythropoietin in urine for doping analysis: Interpretation of isoelectric profiles by discriminant analysis. Electrophoresis 2007, 28, 1875.
79. M. Lonnberg, M. Andren, G. Birgegard, M. Drevin, M. Garle, J. Carlsson Rapid detection of erythropoiesis-stimulating agents in urine and serum. Anal. Biochem. 2012, 420, 101.
80. J.M. Sue, A.J. Sytkowski Site-specific antibodies to human erythropoietin directed toward the NH2-terminal region. Proc. Natl. Acad. Sci. USA 1983, 80, 3651.
81. W. Jelkmann Biosimilar epoetins and other 'follow-on' biologics: Update on the European experiences. Am. J. Hematol. 2010, 85, 771.
82. R.B. Stead, J. Lambert, D. Wessels, J.S. Iwashita, K.K. Leuther, K.W. Woodburn, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006, 108, 1830.
83. E. Bouman-Thio, K. Franson, B. Miller, J. Getsy, A. Cohen, S.A. Bai, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J. Clin. Pharmacol. 2008, 48, 1197.
84. P.J. Bugelski, R.J. Capocasale, D. Makropoulos, D. Marshall, P.W. Fisher, J. Lu, et al. CNTO 530: Molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J. Biotechnol. 2008, 134, 171.
85. C-H. Joung, J-Y. Shin, J-K. Koo, J.J. Lim, J-S. Wang, S-J. Lee, et al. Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein. Express. Purif. 2009, 68, 137.
86. K. Schriebl, E. Trummer, C. Lattenmayer, R. Weik, R. Kunert, D. Müller, et al. Biochemical characterization of rhEPO-Fc fusion protein expressed in CHO cells. Protein Express. Purif. 2006, 49, 265.
87. F. Fares, S. Ganem, T. Hajouj, E. Agai Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. Endocrinology 2007, 148, 5081.
88. A.J. Sytkowski, E.D. Lunn, K.L. Davis, L. Feldman, S Siekman Human erythropoietin dimers with markedly enhanced in vivo activity. Proc. Natl Acad. Sci. USA 1998, 95, 1184.
89. A.J. Sytkowski, E.D. Lunn, M.A. Risinger, K.L. Davis An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J. Biol. Chem. 1999, 274, 24773.
90. A. Coscarella, C. Carloni, R. Liddi, S. Mauro, S. Novelli, A. Mele, et al. Production of recombinant human GM-CSF-EPO hybrid proteins: In vitro biological characterization. Eur. J. Haematol. 1997, 59, 238.
91. N.S. Weich, J. Tullai, E. Guido, M. McMahon, L.K. Jolliffe, A.F. Lopez, et al. Interleukin-3/erythropoietin fusion proteins: In vitro effects on hematopoietic cells. Exp. Hematol. 1993, 21, 647.
92. N.D. Taylor, J.C. Way, P.A. Silver, P. Cironi Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity. Protein Eng. Des. Sel. 2010, 23, 251.
93. R.J. Boado, E.K-W. Hui, J.Z. Lu, W.M. Pardridge Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular trojan horse. J. Pharmacol. Exp. Ther. 2010, 333, 961.
94. H.F. Bunn, J. Gu, L.E. Huang, J.W. Park, H. Zhu Erythropoietin: a model system for studying oxygen-dependent gene regulation. J. Exp. Biol. 1998, 201, 1197.
95. Z. Cai, D.J. Manalo, G. Wei, E.R. Rodriguez, K. Fox-Talbot, H. Lu, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003, 108, 79.
96. J.R. Curtis, G.C. Goode, J. Herrington, L.E. Urdaneta Possible cobalt toxicity in maintenance hemodialysis patients after treatment with cobaltous chloride: A study of blood and tissue cobalt concentrations in normal subjects and patients with terminal and renal failure. Clin. Nephrol. 1976, 5, 61.
97. L. Yan, V.J. Colandrea, J.J. Hale Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Exp. Opin. Ther. Pat. 2010, 20, 1219.
98. W.M. Bernhardt, M.S. Wiesener, P. Scigalla, J. Chou, R.E. Schmieder, V. Gunzler, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J. Am. Soc. Nephrol. 2010, 21, 2151.
99. Y. Nakano, S. Imagawa, K. Matsumoto, C. Stockmann, N. Obara, N. Suzuki, et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood 2004, 104, 4300.
100. S.M. Rudich, S. Zhou, R. Srivastava, J.A. Escobedo, R.V. Perez, W.C. Manning Dose response to a single intramuscular injection of recombinant adeno-associated virus-Erythropoietin in Monkeys. J. Surg. Res. 2000, 90, 102.
101. C.J. Beall, A.J. Phipps, L.E. Mathes, P. Stromberg, P.R. Johnson Transfer of the feline erythropoietin gene to cats using a recombinant adeno-associated virus vector. Gene Ther. 2000, 7, 534.
102. E.C. Svensson, H.B. Black, D.L. Dugger, S.K. Tripathy, E. Goldwasser, Z. Hao, et al. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector. Hum. Gene Ther. 1997, 8, 1797.
103. P. Chenuaud, T. Larcher, J.E. Rabinowitz, N. Provost, Y. Cherel, N. Casadevall, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004, 103, 3303.
104. V.M. Rivera, G.P. Gao, R.L. Grant, M.A. Schnell, P.W. Zoltick, L.W. Rozamus, et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 2005, 105, 1424.
105. K. Binley, Z. Askham, S. Iqball, H. Spearman, L. Martin, M. de Alwis, et al. Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy. Blood 2002, 100, 2406.
106. Y. Lippin, M. Dranitzki-Elhalel, E. Brill-Almon, C. Mei-Zahav, S. Mizrachi, Y. Liberman, et al. Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005, 106, 2280.
107. F. Lasne, L. Martin, J. de Ceaurriz, T. Larcher, P. Moullier, P. Chenuaud "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. Mol. Ther. 2004, 10, 409.
108. R.R. Romanowski, A.J. Sytkowski The molecular structure of human erythropoietin. Hematol. Oncol. Clin. N. 1994, 8, 885.